Market revenue in 2023 | USD 161.7 million |
Market revenue in 2030 | USD 296.7 million |
Growth rate | 9.1% (CAGR from 2023 to 2030) |
Largest segment | Diagnostics |
Fastest growing segment | Therapeutics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Diagnostics, Therapeutics |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Jubilant Pharmova, Nordion, Bracco, Iren SpA, Abliva AB, Lantheus Holdings Inc, Eckert & Ziegler Bebig SA, Mallinckrodt PLC Ordinary Shares - New, Cardinal Health Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to nuclear medicine market will help companies and investors design strategic landscapes.
Diagnostics was the largest segment with a revenue share of 78.73% in 2023. Horizon Databook has segmented the South Korea nuclear medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
Currently, South Korea imports Mo-99 from Russia, South Africa, and Australia to meet the needs of consumers. The demand for nuclear medicines in the country is expected to increase steadily over the forecast period. In line with this, in 2012, the Korean government launched a new research project Kijang Research Reactor (KJRR) to produce Mo-99, Ir-192, I-131, and other medical radioisotopes.
Furthermore, in May 2019, South Korea approved the construction of a radioactive isotope research reactor in Gijang, South Korea. It is expected to be completed by 2024. According to the Ministry of Science and ICT and the Nuclear Safety and Security Commission, the government funded 439 billion Won (373 USD million) for this project.
In addition, increasing number of initiatives undertaken by key players is expected to propel market growth. For instance, in July 2018, GE Healthcare installed its 400th cyclotron PET trace 880 at the Korea Institute of Radiological & Medical Sciences (KIRAMS). Until July 2018, a total of 43 cyclotrons were installed at healthcare centers across the country.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea nuclear medicine market , including forecasts for subscribers. This country databook contains high-level insights into South Korea nuclear medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account